Comparative Pharmacology
Head-to-head clinical analysis: CABERGOLINE versus MIRAPEX ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABERGOLINE versus MIRAPEX ER.
CABERGOLINE vs MIRAPEX ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
Non-ergot dopamine agonist with high affinity for D2 and D3 receptor subtypes; stimulates dopamine receptors in the striatum.
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
Oral, start 0.375 mg once daily, titrate weekly by 0.375 mg/dose to 1.5 mg once daily (immediate-release); ER: same total daily dose once daily.
None Documented
None Documented
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
Clinical Note
moderateCabergoline + Digoxin
"Cabergoline may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabergoline + Digitoxin
"Cabergoline may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabergoline + Deslanoside
"Cabergoline may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCabergoline + Acetyldigitoxin
"Cabergoline may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 8–12 hours in young healthy adults; prolonged to 16–40 hours in elderly (≥65 years) and up to 30 hours in moderate renal impairment (CrCl 20–50 mL/min).
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
Renal excretion of unchanged drug and metabolites: ~90% in urine (pramipexole: ~70% unchanged; N-desmethyl metabolite: ~20%). Fecal excretion: ~2%. Biliary elimination: minimal.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist